Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
UNIVERSITE COTE D'AZUR currently manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending actions are split between 2 distinct examiners, providing a diversified review process. Furthermore, the prosecution is taking place across 2 distinct art units, which indicates that the university's patent applications are being evaluated by different specialized technical groups within the patent office.
The busiest examiner identified is REYNOLDS, FRED H, who is responsible for 1 busiest examiner pending office action. With a total of 2 pending office actions in the portfolio, REYNOLDS, FRED H handles a portion of the current workload, while the remaining portion is managed by the other of the 2 distinct examiners. This distribution across 2 distinct examiners and 2 distinct art units requires a flexible prosecution strategy. Practitioners must address the specific requirements and examination styles of 2 different individuals and 2 different technical units simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
| SIMMONS, CHRIS E | 1 | 34.1% | +19.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17603997 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | SIMMONS, CHRIS E | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17603997 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | SIMMONS, CHRIS E | 56d |
| 17758540 | RSPO1 PROTEINS AND THEIR USE | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17758540 | RSPO1 PROTEINS AND THEIR USE | REYNOLDS, FRED H | 1658 | §102DP | Non-Final OA | — | Pending | Jul 08, 2022 |
| 17603997 | METHODS AND COMPOSITIONS FOR TREATMENT OF NLRP3 INFLAMMASOME MEDIATED IL-1BETA DEPENDENT DISORDERS | SIMMONS, CHRIS E | 1622 | §103§112 | Final Rejection | 56d | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial